智通财经APP获悉，据媒体消息称，宜联生物正寻求就旗下抗体偶联药物(ADC)YL201，与一家全球制药公司达成授权协议，这将为公司最快2026年在香港上市铺路。消息指，蹉商仍在进行中，未必可以达成协议。
据了解，宜联生物是一家专注于ADC和相关技术的创新药物开发公司。公司在上海和波士顿设有研发中心。
YL201是一款靶向B7H3的ADC药物。目前，YL201正在全球范围内开展针对多种实体瘤的探索性研究。其中，小细胞肺癌、鼻咽癌适应症在中国已进入关键临床III期研究阶段。同时，YL201也在积极开展多种联用试验，探索其在多种实体瘤的前线治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.